C16orf78

Across TCGA pan-cancer cohorts, C16orf78 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C16orf78 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher C16orf78 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C16orf78 expression acts as an unfavorable survival marker.

LIHC, ESCA, and LUSC are the cancer types where C16orf78 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.093	0.716	<.001	18	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	15	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C16orf78–LIHC (OS)

Open the LIHC breakdown →